Nima Nabavizadeh

Dr. Nima Nabavizadeh serves as Associate Professor of Radiation Medicine at Oregon Health & Science University (OHSU) School of Medicine, where he holds dual leadership roles as Chief Medical Officer of the Cancer Early Detection Advanced Research Center (CEDAR) and Radiation Oncology Residency Program Director. His clinical expertise focuses on gastrointestinal cancers, lymphomas, and hematologic malignancies, delivering personalized radiation therapy while advancing early cancer detection research through CEDAR's clinical trials.

Dr. Nabavizadeh's academic journey includes:

• M.D. from University of Oklahoma College of Medicine (2011)
• Radiation Oncology Residency at OHSU (2016)
• Doris Duke Charitable Foundation Clinical Research Fellowship at UCSF (2009)
• American Board of Radiology Certification (2017)

His research pioneers blood-based multi-cancer early detection tests, particularly for gastrointestinal malignancies and lymphomas, with emphasis on translating liquid biopsy technologies into clinical practice. Current work explores stereotactic radiation techniques for liver and pancreatic cancers while optimizing neoadjuvant regimens for esophageal and gastroesophageal junction tumors.

Analysis of his 15 most recent publications reveals dominant themes in gastrointestinal oncology (68%), early cancer detection (22%), and lymphoma management (10%), with growing emphasis on health economics of novel screening technologies and geographic disparities in cancer care access. Methodologically, 73% involve clinical trial data with increasing integration of circulating tumor DNA analysis.

As Residency Program Director, Dr. Nabavizadeh mentors radiation oncology trainees through OHSU's accredited program, developing curricula that integrate virtual rotations and advanced radiation techniques. His research is supported by multiple clinical trial grants focused on early detection biomarkers and radiation optimization.

He leads CEDAR's clinical research initiatives, directing trials that validate multi-cancer blood tests while collaborating with molecular diagnostics teams to refine detection algorithms for liver and pancreatic cancers.